Appendicealmucinous neoplasms: Diagnosis andmanagement

Oncologist

Volumn 22, Issue 9, 2017, Pages 1107-1116

  Shaib, Walid L ^a,b   Assi, Rita ^c   Shamseddine, Ali ^c   Alese, Olatunji B ^a,b   Staley, Charles ^a   Memis, Bahar ^a   Adsay, Volkan ^a   Bekaii Saab, Tonios ^d   El Rayes, Bassel F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d MAYO CLINIC   (United States)

Author keywords

Abdominal surgery; Appendix carcinoma; Review

Indexed keywords

CAPECITABINE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; MUCIN; OXALIPLATIN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; APPENDICEAL MUCINOUS NEOPLASM; APPENDICITIS; APPENDIX PERFORATION; APPENDIX TUMOR; BASE MISPAIRING; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COPY NUMBER VARIATION; CRYPT CELL; CYTOREDUCTIVE SURGERY; DISEASE COURSE; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; INCIDENCE; MICROSATELLITE INSTABILITY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; APPENDIX; CLASSIFICATION; COLLOID CARCINOMA; PATHOLOGY; PRACTICE GUIDELINE; RARE DISEASE; SURGERY; THERMOTHERAPY; TREATMENT OUTCOME;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; APPENDIX; CYTOREDUCTION SURGICAL PROCEDURES; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RARE DISEASES; TREATMENT OUTCOME;

EID: 85029649368     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0081     Document Type: Review

References (71)

1. McCusker ME, Cote TR, Clegg LX et al. Primary malignant neoplasms of the appendix: A populationbased study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer 2002; 94:3307–3312.
2. Smeenk RM, van Velthuysen ML, Verwaal VJ et al. Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. Eur J Surg Oncol 2008;34:196–201.
3. Rokitansky K, Swaine WE, Sir Sieveking EH, Moore CH, Day GE. A Manual of Pathological Anatomy. Vol. 2. Philadelphia, PA: Blanchard and Lea, 1855;24:100–118.
4. Elting AW. IX. Primary carcinoma of the vermiform appendix, with a report of three cases. Ann Surg 1903;37:549–574.
5. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer 1995;75:757–768.
6. Ronnett BM, Zahn CM, Kurman RJ et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 1995;19:1390–1408.
7. Pai RK, Beck AH, Norton JA et al. Appendiceal mucinous neoplasms: Clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol 2009;33:1425–1439.
8. Misdraji J, Yantiss RK, Graeme-Cook FM et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27:1089–1103.
9. Overman MJ, Fournier K, Hu CY et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histological grade. Ann Surg 2013;257:1072–1078.
10. Carr NJ, Cecil TD, Mohamed F et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The results of the Peritoneal Surface Oncology Group International (PSOGI) modified delphi process. AmJ Surg Pathol 2016;40:14–26.
11. Gupta S, Parsa V, Adsay V et al. Clinicopathological analysis of primary epithelial appendiceal neoplasms. Med Oncol 2010;27:1073–1078.
12. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol 2004;21:134–150.
13. Collins DC. 71, 000 human appendix specimens. A final report, summarizing forty years’ study. Am J Proctol 1963;14:265–281.
14. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: Retrospective clinicopathologic analysis of appendiceal tumors from 7, 970 appendectomies. Dis Colon Rectum 1998;41:75–80.
15. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
16. Ozakyol AH, Saricam T, Kabukcuoglu S et al. Primary appendiceal adenocarcinoma. Am J Clin Oncol 1999;22:458–459.
17. Shaib WL, Goodman M, Chen Z et al. Incidence and survival of appendiceal mucinous neoplasms: A SEER analysis. Am J Clin Oncol 2015 [Epub ahead of print].
18. van den Heuvel MG, Lemmens VE, Verhoeven RH et al. The incidence of mucinous appendiceal malignancies: A population-based study. Int J Colorectal Dis 2013;28:1307–1310.
19. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76.
20. Ito H, Osteen RT, Bleday R et al. Appendiceal adenocarcinoma: Long-term outcomes after surgical therapy. Dis Colon Rectum 2004;47:474–480.
21. Bradley RF, Stewart JH 4th, Russell GB et al. Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551–559.
22. Garg PK, Prasad D, Aggarwal S et al. Acute intestinal obstruction: An unusual complication of mucocele of appendix. Eur Rev Med Pharmacol Sci 2011;15:99–102.
23. Rutledge RH, Alexander JW. Primary appendiceal malignancies: Rare but important. Surgery 1992;111:244–250.
24. Reid MD, Basturk O, Shaib WL et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: An analysis of 77 cases. Mod Pathol 2016;29:1243–1253.
25. Kabbani W, Houlihan PS, Luthra R et al. Mucinous and nonmucinous appendiceal adenocarcinomas: Different clinicopathological features but similar genetic alterations. Mod Pathol 2002;15: 599–605.
26. Muller D. Appendiceal neoplasm resulting from a malignant transformation of a villous adenoma [in German]. Chirurg 1980;51:609–610.
27. Stewart JH 4th, Shen P, Russell GB et al. Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:624–634.
28. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012;19:1379–1385.
29. Nitecki SS, Wolff BG, Schlinkert R et al. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51–57.
30. Ronnett BM, Yan H, Kurman RJ et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92:85–91.
31. Esquivel J, Sugarbaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg 2000;87:1414–1418.
32. Higa E, Rosai J, Pizzimbono CA et al. Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the appendix. A reevaluation of appendiceal “mucocele”. Cancer 1973; 32:1525–1541.
33. Misdraji J. Appendiceal mucinous neoplasms: Controversial issues. Arch Pathol Lab Med 2010;134: 864–870.
34. Ji H, Isacson C, Seidman JD et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391–400.
35. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–170.
36. Perucho M. Microsatellite instability: The mutator that mutates the other mutator. Nat Med 1996;2:630–631.
37. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87: 1114–1125.
38. Chung DC. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854–865.
39. Szych C, Staebler A, Connolly DC et al. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. AmJ Pathol 1999;154:1849–1855.
40. Raghav KP, Shetty AV, Kazmi SM et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. The Oncologist 2013;18:1270–1277.
41. Goldstein D EJ, Wang K, et al. Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies. J Clin Oncol 2015; 33(suppl 3):608a.
42. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D’Agostino R, Shen P, Miller LD. Prognostic molecular subtypes of lowgrade cancer of the appendix. J Am Coll Surg 2016; 222:493–503.
43. American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science BusinessMedia.
44. Yantiss RK, Shia J, Klimstra DS et al. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol 2009;33:248–255.
45. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004;91:304–311.
46. Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. World J Surg Oncol 2005;3:36.
47. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. AmJ Surg Pathol 1991;15:415–429.
48. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256–260.
49. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42.
50. Jacquet P, Stephens AD, Averbach AM et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622–2629.
51. Gerweck LE. Hyperthermia in cancer therapy: The biological basis and unresolved questions. Cancer Res 1985;45:3408–3414.
52. Lindquist S. The heat-shock response. Annu Rev Biochem 1986;55:1151–1191.
53. Oleson JR, Calderwood SK, Coughlin CT et al. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 1988;11: 368–380.
54. Chua TC, Moran BJ, Sugarbaker PH et al. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–2456.
55. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–374.
56. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–132.
57. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6: 727–731.
58. Gough DB, Donohue JH, Schutt AJ et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112–119.
59. Dayal S, Taflampas P, Riss S et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2013;56:1366–1372.
60. Shaib WL, Martin LK, Choi M et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: A pooled analysis from three tertiary care centers. The Oncologist 2015;20:907–914.
61. Baratti D, Kusamura S, Deraco M. The Fifth InternationalWorkshop on Peritoneal SurfaceMalignancy (Milan, Italy, December 4–6, 2006):Methodology of disease-specific consensus. J Surg Oncol 2008; 98:258–262.
62. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008; 15:526–534.
63. Sugarbaker PH, Bijelic L, Chang D et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients withmucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010;102:576–581.
64. Esquivel J, Chua TC, Stojadinovic A et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: A multi-institutional study. J Surg Oncol 2010;102: 565–570.
65. Bijelic L, Kumar AS, Stuart OA et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: Impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract 2012;2012:163284.
66. Farquharson AL, Pranesh N, Witham G et al. A phase II study evaluating the use of concurrentmitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591–596.
67. Livingston EH, Woodward WA, Sarosi GA et al. Disconnect between incidence of nonperforated and perforated appendicitis: Implications for pathophysiology and management. Ann Surg 2007;245: 886–892.
68. Pietrantonio F, Maggi C, Fanetti G et al. FOLFOX- 4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. The Oncologist 2014;19:845–850.
69. Shapiro JF, Chase JL, Wolff RA et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: A single-institution experience. Cancer 2010;116:316–322.
70. Logan-Collins JM, Lowy AM, Robinson-Smith TM et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008;15:738–744.
71. Lieu CH, Lambert LA, Wolff RA et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012;23:652–658.